Compare GDDY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | PODD |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 10.3B |
| IPO Year | 2014 | 2007 |
| Metric | GDDY | PODD |
|---|---|---|
| Price | $92.55 | $163.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | $136.44 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.60 | 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $7.94 | $24.55 |
| Revenue Next Year | $6.10 | $19.18 |
| P/E Ratio | ★ $54.76 | $121.83 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $71.59 | $138.79 |
| 52 Week High | $167.09 | $354.88 |
| Indicator | GDDY | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 55.69 |
| Support Level | $81.16 | $141.67 |
| Resistance Level | $93.58 | $168.84 |
| Average True Range (ATR) | 3.75 | 5.46 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 69.95 | 65.67 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.